← Back to Search

Immunomodulator

Active EC-18 for Coronavirus Pneumonia

Phase 2
Waitlist Available
Research Sponsored by Enzychem Lifesciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7, 14, and 28 days
Awards & highlights

Study Summary

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

Eligible Conditions
  • Coronavirus Pneumonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7, 14, and 28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7, 14, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of patients alive and free of respiratory failure through at Day 28
Secondary outcome measures
Assessment of all-cause mortality
Confirmation of changes in subject's subjective clinical symptoms (e.g., patient questionnaire)
Lengths of ICU stay
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active EC-18Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mosedipimod
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Enzychem Lifesciences CorporationLead Sponsor
6 Previous Clinical Trials
329 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~15 spots leftby Apr 2025